1Jones PW,Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease(J~. Eur Respir J ,2006 ;27 (4) :822-32.
2Mildvan D, Landay A, De Gruttola V, et al. An approach to the validation of markers for use in AIDS clinical trials [ J]. Clin Infect Dis, 1997 ;24 ( 5 ) :764-74.
4Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, prevention of chronic obstructive pulmonary disease. NHBL/WHO Global Chronic Obstructive Lung Disease (GOLD) Workshop summary [ J ]. Am J Respir Crit Care Med, 2001 ; 163 (5) : 1256-76.
5Wise RA. The value of forced expiratory volume in lsecond decline in the assessment of chronic obstructive pulmonary disease progression[ J]. Am J Med,2006;119(10A) :s4-11.
6Gross NJ. Outcome measures for COPD treatments : a critical evaluation [J]. COPD,2004;1:41-57.
7Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD : a summary of the ATS/ERS position paper[ J]. Eur Respir J,2004 ;23 (6) :93246.
8Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6 minute-walk test in chronic obstructive pulmonary disease[ J]. Am J Respir Crit Care Med,2001 ;163(6) :1395-9.
9Redelmeier DA, Bayoumi AM, Goldstein RS, et al. Interpreting small differences in functional status:the six Ninute Walk Test in chronic lung disease patients[ J]. Am J Respir Crit Care Med,1997;155(4) :1278-82.
10Carter R, Holiday DB, Nwasuruba C, et al. 6-Minute Walk Work for assessment of functional capacity in patients with COPD( J). Chest,2003 ; 123(5) :1408-15.
